MX358198B - Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino. - Google Patents

Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino.

Info

Publication number
MX358198B
MX358198B MX2015015682A MX2015015682A MX358198B MX 358198 B MX358198 B MX 358198B MX 2015015682 A MX2015015682 A MX 2015015682A MX 2015015682 A MX2015015682 A MX 2015015682A MX 358198 B MX358198 B MX 358198B
Authority
MX
Mexico
Prior art keywords
inflammatory bowel
bowel disease
treatment
thiazolo
pyrimidinone
Prior art date
Application number
MX2015015682A
Other languages
English (en)
Spanish (es)
Other versions
MX2015015682A (es
Inventor
Chaitanya Dutt
Vijay Chauthaiwale
Ram Gupta
Shitalkumar Zambad
Shailesh Deshpande
Jignesh Kotecha
Ramesh Gupta
Sanjay Srivastava
Laxmikant Chhipa
Jaya Abraham
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of MX2015015682A publication Critical patent/MX2015015682A/es
Publication of MX358198B publication Critical patent/MX358198B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
MX2015015682A 2013-05-14 2014-05-12 Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino. MX358198B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1718MU2013 2013-05-14
IN2309MU2013 2013-07-09
PCT/IB2014/000707 WO2014184631A1 (en) 2013-05-14 2014-05-12 Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease

Publications (2)

Publication Number Publication Date
MX2015015682A MX2015015682A (es) 2016-07-20
MX358198B true MX358198B (es) 2018-08-08

Family

ID=50896342

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015682A MX358198B (es) 2013-05-14 2014-05-12 Uso de una tiazolo-pirimidinona para el tratamiento de enfermedad inflamatoria del intestino.

Country Status (28)

Country Link
US (2) US9610247B2 (OSRAM)
EP (1) EP2996693B1 (OSRAM)
JP (1) JP6407974B2 (OSRAM)
KR (1) KR102239649B1 (OSRAM)
CN (1) CN105209043B (OSRAM)
AU (1) AU2014266968B2 (OSRAM)
BR (1) BR112015028581B1 (OSRAM)
CA (1) CA2912011C (OSRAM)
CY (1) CY1121280T1 (OSRAM)
DK (1) DK2996693T3 (OSRAM)
EA (1) EA030590B1 (OSRAM)
ES (1) ES2712705T3 (OSRAM)
HR (1) HRP20190315T1 (OSRAM)
HU (1) HUE042691T2 (OSRAM)
IL (1) IL242490B (OSRAM)
LT (1) LT2996693T (OSRAM)
MX (1) MX358198B (OSRAM)
MY (1) MY179215A (OSRAM)
PH (1) PH12015502560B1 (OSRAM)
PL (1) PL2996693T3 (OSRAM)
PT (1) PT2996693T (OSRAM)
RS (1) RS58423B1 (OSRAM)
SG (1) SG11201509275PA (OSRAM)
SI (1) SI2996693T1 (OSRAM)
SM (1) SMT201900111T1 (OSRAM)
TW (1) TWI661828B (OSRAM)
UA (1) UA117244C2 (OSRAM)
WO (1) WO2014184631A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781922B (zh) * 2016-03-14 2022-11-01 日商參天製藥股份有限公司 由葡甲胺或其鹽構成之防腐劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
US8541430B2 (en) * 2009-11-27 2013-09-24 Torrent Pharmaceuticals Limited Fused thiazolo and oxazolo pyrimidinones

Also Published As

Publication number Publication date
CN105209043B (zh) 2019-07-02
HRP20190315T1 (hr) 2019-04-05
PL2996693T3 (pl) 2019-05-31
CA2912011A1 (en) 2014-11-20
SG11201509275PA (en) 2015-12-30
AU2014266968A1 (en) 2015-12-03
US20160120801A1 (en) 2016-05-05
SI2996693T1 (sl) 2019-04-30
ES2712705T3 (es) 2019-05-14
PH12015502560A1 (en) 2016-02-22
EP2996693B1 (en) 2018-12-12
IL242490B (en) 2018-11-29
US20170157129A1 (en) 2017-06-08
EA030590B1 (ru) 2018-08-31
AU2014266968B2 (en) 2019-09-19
EA201592159A1 (ru) 2016-04-29
US10471005B2 (en) 2019-11-12
CN105209043A (zh) 2015-12-30
US9610247B2 (en) 2017-04-04
UA117244C2 (uk) 2018-07-10
TW201513866A (zh) 2015-04-16
BR112015028581B1 (pt) 2022-05-03
KR102239649B1 (ko) 2021-04-12
KR20160008571A (ko) 2016-01-22
SMT201900111T1 (it) 2019-02-28
TWI661828B (zh) 2019-06-11
MY179215A (en) 2020-11-02
BR112015028581A2 (pt) 2017-07-25
MX2015015682A (es) 2016-07-20
PH12015502560B1 (en) 2016-02-22
PT2996693T (pt) 2019-02-27
HUE042691T2 (hu) 2019-07-29
DK2996693T3 (en) 2019-03-18
NZ714098A (en) 2020-12-18
JP6407974B2 (ja) 2018-10-17
LT2996693T (lt) 2019-03-12
CY1121280T1 (el) 2020-05-29
EP2996693A1 (en) 2016-03-23
WO2014184631A1 (en) 2014-11-20
CA2912011C (en) 2021-10-26
JP2016518440A (ja) 2016-06-23
RS58423B1 (sr) 2019-04-30

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
GB201118656D0 (en) New compounds
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2013012588A (es) Inhibidores de cinasa.
MX349004B (es) Nuevos compuestos.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
TW201129361A (en) Methods for treating pain
EA201591704A1 (ru) Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
PH12015502560A1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
MX2014011843A (es) Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.

Legal Events

Date Code Title Description
FG Grant or registration